Search Results - "ter Meulen, C. G"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    Toxoplasmosis after Renal Transplantation: Implications of a Missed Diagnosis by Wulf, M. W. H, van Crevel, R, Portier, R, ter Meulen, C. G, Melchers, W. J. G, van der Ven, A, Galama, J. M. D

    Published in Journal of Clinical Microbiology (01-07-2005)
    “…We describe a renal transplant patient with a primary Toxoplasma gondii infection presenting as pneumonitis, with subsequent chorioretinitis and encephalitis…”
    Get full text
    Journal Article
  2. 2

    The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation by ter Meulen, Cornelis G., Wetzels, Jack F. M., Hilbrands, Luuk B.

    Published in Nephrology, dialysis, transplantation (01-05-2000)
    “…Background. Mycophenolate mofetil (MMF) is increasingly used for immunosuppression after renal transplantation (RTx). The aim of our study was to investigate…”
    Get full text
    Journal Article
  3. 3

    Flaccid paresis due to distal renal tubular acidosis preceding systemic lupus erythematosus by TER MEULEN, C. G, PIETERS, G. F. F. M, HUYSMANS, F. T. M

    Published in Netherlands journal of medicine (01-03-2002)
    “…We report a 25-year-old woman presenting with a flaccid paresis due to severe hypokalaemia as a consequence of distal renal tubular acidosis (dRTA). Six years…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Urinary epidermal growth factor excretion is correlated to renal function loss per se and not to the degree of diabetic renal failure by ter Meulen, C G, Bilo, H J, van Kamp, G J, Gans, R O, Donker, A J

    Published in Netherlands journal of medicine (01-01-1994)
    “…Urinary epidermal growth factor (EGF) excretion is seen as a marker of tubular function, and some studies conclude that EGF excretion can already be reduced…”
    Get more information
    Journal Article
  7. 7

    Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone by ter Meulen, C G, Gregoor, P J, Weimar, W, Hilbrands, L B

    Published in Transplant international (2001)
    “…In a retrospective study we investigated the risk of acute rejection after the withdrawal of mycophenolate mofetil (MMF) in 39 adult patients treated with…”
    Get more information
    Journal Article
  8. 8

    Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil by VAN GELDER, Teun, TER MEULEN, Cornelis G, HENE, Ronald, WEIMAR, Willem, HOITSMA, Andries

    Published in Transplantation (27-03-2003)
    “…In an attempt to reduce calcineurin inhibitor toxicity, transplant patients treated with tacrolimus can be switched to maintenance treatment with sirolimus. In…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation by TER MEULEN, Cornelis G, HILBRANDS, Luuk B, VAN DEN BERGH, Joop P. W, HERMUS, Ad R, HOITSMA, Andries J

    Published in Osteoporosis international (01-03-2005)
    “…Steroid-related bone loss is a recognized complication after renal transplantation. Quantitative ultrasound (QUS) of bone measures bone structure besides bone…”
    Get full text
    Journal Article
  14. 14

    The fractional excretion of soluble interleukin-2 receptor-α is an excellent predictor of the interleukin-2 receptor-α status after treatment with daclizumab by TER MEULEN, Cornelis G, JACOBS, Cor W. M, WETZELS, Jack F. M, KLASEN, Ina S, HILBRANDS, Luuk B, HOITSMA, Andries J

    Published in Transplantation (27-01-2004)
    “…Daclizumab is a humanized monoclonal antibody against the alpha-chain of the interleukin (IL)-2 receptor (R). The authors previously have shown that the…”
    Get full text
    Journal Article
  15. 15

    The fractional excretion of soluble interleukin-2 receptor-?? is an excellent predictor of the interleukin-2 receptor-?? status after treatment with daclizumab by ter Meulen, Cornelis G., Jacobs, Cor W. M., Wetzels, Jack F. M., Klasen, Ina S., Hilbrands, Luuk B., Hoitsma, Andries J.

    Published in Transplantation (27-01-2004)
    “…Background. Daclizumab is a humanized monoclonal antibody against the [alpha]-chain of the interleukin (IL)-2 receptor (R). The authors previously have shown…”
    Get full text
    Journal Article
  16. 16

    Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects by ter Meulen, C G, Hilbrands, L B, van Riemsdijk-van Overbeeke, I C, Hené, R J, Christiaans, M H, Hoitsma, A J

    Published in Nederlands tijdschrift voor geneeskunde (09-12-2000)
    “…Four major double-blind randomized trials in kidney transplant patients have shown that the interleukin-2 receptor (IL-2R alpha) antagonists declizumab or…”
    Get more information
    Journal Article